FindTrial
Sign In

Feasibility study of percutaneus endoscopic gastrostomy with Direct IDEAL PEG for patients with active head and neck cancer and esophageal cancer.

Feasibility study of percutaneus endoscopic gastrostomy with Direct IDEAL PEG for patients with active head and neck cancer and esophageal cancer. - Feasibility study of Direct IDEAL PEG

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000542
Enrollment
20
Registered
2007-01-01
Start date
2006-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with active head and neck cancer and esophageal cancer

Interventions

PEG

Sponsors

National Cancer Center Hospital East
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with active head and neck cancer and esophageal cancer performance status:0,1,2 written informed concent laboratory data within 2 weeks before entry WBC > 2500/mm3 Platelet > 7.5x104/mm3 Creatinine>2.0 mg/dl Total bilirubin>3.0 mg/dl AST, ALT>within 5 times of limitation of our hospital

Exclusion criteria

Exclusion criteria: 1. impossible of passage of endoscopy 2. exsisting of fistula 3. after gastrectomy 4. active infection 5. risk of GI bleeding 6. massive ascites 7. disapproval of withdraw of anti coaguration agent 8. addiction of steroids 9. severe heart disease and uncontrolled hypertention and diabete 10. terminal stage within 4 months prognosis 11. ineligible judged by doctor in charge

Design outcomes

Primary

MeasureTime frame
completion rate of PEG—

Secondary

MeasureTime frame
Incidence of adverse event Incidence of severe adverse event—

Countries

Japan

Contacts

Public ContactTomonori Yano

National Cancer Center Hospital East Division Digestive Endoscopy and GI Oncology

toyano@east.ncc.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026